Ventricular Pulsed Field Ablation from Bench to Bedside: Preclinical and Clinical Evidence from a Systematic Review and Meta-Analysis
Clicks: 1
ID: 325560
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #34 of 79 articles by views in EP Europace
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
BACKGROUND AND AIMS: Evidence supporting the use of pulsed field ablation (PFA) for ventricular arrhythmia (VA) ablation remains limited and heterogeneous, and the relationship between preclinical lesion characteristics and clinical outcomes is incompletely defined. We sought to systematically summarize preclinical lesion metrics and clinical outcomes of ventricular PFA. METHODS: We performed a systematic review and meta-analysis of preclinical and clinical studies of ventricular PFA. Preclinical studies reporting lesion depth or transmurality and clinical studies detailing procedural efficacy and safety were included. Random-effects models were used to pool lesion characteristics and clinical outcomes. RESULTS: Seventy-five studies were included (33 preclinical, 43 clinical; 355 patients). In preclinical models, mean lesion depth was 5.96mm(95%CI,5.07-6.84) in healthy endocardium and 5.19mm (95%CI,2.58-7.79) in healthy epicardium. Notably, lesion depth was quantitatively similar in models of scarred myocardium (5.96mm; 95%CI,5.39-6.53). Lesion transmurality was variable in healthy tissues (32%; 95%CI,15%-52%) but higher within scar (53%; 95%CI,36%-70%). Consistently, lesion depth was similar between PFA and RF in healthy myocardium, but greater with PFA in scarred models (within-study mean depth difference, 2.09mm; 95%CI,0.84-3.34). Greater contact force, repeated applications, and higher energy/duration settings were associated with increased lesion depth. Clinically, acute success was high for both premature ventricular complexes (PVCs,90%; 95%CI,83%-96%) and ventricular tachycardia (VT;92%; 95%CI,87%-96%) in studies with ≥3patients. Over a mean follow-up of approximately 5months, recurrence rates were 19% (95%CI,12%-28%) for PVCs and 21% (95%CI,10%-35%) for VT. The overall complication rate was 10% (95%CI,5%-17%) in studies with ≥3patients, with coronary artery spasm and conduction disturbances representing the most frequent adverse events. CONCLUSION: Ventricular PFA demonstrates high acute efficacy and encouraging mid-term outcomes, supported by preclinical evidence of favorable lesion penetration within scarred myocardium. Safety considerations-particularly coronary and conduction system effects-and the heterogeneity of preclinical evidence highlight the need for further investigation.
| Reference Key |
openalex_W7203731706
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Paolo Compagnucci, Luca Finori, Michela Casella, Alessio Gasperetti, Henry D Huang, Yari Valeri, Leonardo D’Angelo, Francesca Campanelli, Giorgio Giacomini, Giovanni Volpato, Laura Cipolletta, Quintino Parisi, Luigi Di Biase, Sanghamitra Mohanty, Pasquale Santangeli, Antonio Dello Russo |
| Journal | EP Europace |
| Year | 2026 |
| DOI |
10.1093/europace/euag221
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.